Global rIL-13 administration is overall beneficial to cardiac function after MI, but rIL-13 administration in the absence of macrophage IL-4Rα/IL-13Rα1 is detrimental, resulting in larger scars after MI and a trend toward decreased survival compared with vehicle treatment alone. The gene discussed is IL4R; the disease is myocardial infarction.